Australia's Telix rises after dosing first US patients with brain cancer imaging drug

Telix Pharmaceuticals

07/10/2026 02:04

** Shares of Australia's Telix Pharmaceuticals TLX.AX rise as much as 5.5% to A$16.26, posting their biggest intraday pct gain since Sept 22
** Stock hits highest level since Sept 30
** Stock among top gainers in the broader index .AXJO, which is flat
** After market hours on Tuesday, biopharma co said first patients in the US had been dosed with Pixclara
** Pixclara is co's FDA-approved drug for glioma (brain cancer) imaging
** Pixclara was assigned orphan drug status by the FDA in late 2020, a special designation encouraging development of treatments for rare diseases
** YTD, TLX up nearly 43%

 (Reporting by Aamir Sheik Khalid in Bengaluru)
 ((Aamir.SheikKhalid@thomsonreuters.com))